clomipramine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
substances of the imipramine group 701 303-49-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clomipramine
  • chlorimipramine
  • clomipramine hydrochloride
  • clomipramine HCl
A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
  • Molecular weight: 314.86
  • Formula: C19H23ClN2
  • CLOGP: 5.92
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.34
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.24 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 51 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 13 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 26 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1989 FDA MALLINCKRODT LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 202.70 16.97 133 10277 56746 50537968
Intentional overdose 179.65 16.97 128 10282 62376 50532338
Serotonin syndrome 174.07 16.97 90 10320 24623 50570091
Drug interaction 146.30 16.97 192 10218 199429 50395285
Overdose 118.32 16.97 123 10287 99604 50495110
Bezoar 115.54 16.97 31 10379 1317 50593397
Suicide attempt 108.83 16.97 88 10322 51644 50543070
Poisoning deliberate 99.50 16.97 43 10367 7869 50586845
Intentional self-injury 94.49 16.97 59 10351 23053 50571661
Depressed level of consciousness 87.94 16.97 78 10332 51875 50542839
Toxicity to various agents 86.79 16.97 156 10254 212343 50382371
Antipsychotic drug level increased 82.29 16.97 29 10381 3080 50591634
Neuroleptic malignant syndrome 71.10 16.97 38 10372 11092 50583622
Sopor 67.09 16.97 45 10365 19834 50574880
Tachycardia 63.80 16.97 90 10320 99673 50495041
Antidepressant drug level increased 58.43 16.97 13 10397 248 50594466
Electrocardiogram QT prolonged 57.88 16.97 62 10348 51824 50542890
Pain 52.43 16.97 27 10383 578876 50015838
Hypertonia 51.28 16.97 22 10388 3951 50590763
Cerebellar syndrome 48.29 16.97 20 10390 3291 50591423
Myoclonus 47.02 16.97 32 10378 14438 50580276
Tremor 46.33 16.97 84 10326 114819 50479895
Sinus tachycardia 44.17 16.97 36 10374 21318 50573396
Agitation 43.08 16.97 54 10356 53330 50541384
Somnolence 43.02 16.97 97 10313 154888 50439826
Confusional state 42.59 16.97 108 10302 185820 50408894
Livedo reticularis 41.71 16.97 16 10394 2156 50592558
Suicidal ideation 41.50 16.97 54 10356 55331 50539383
Akathisia 41.36 16.97 24 10386 8205 50586509
Altered state of consciousness 41.29 16.97 35 10375 21875 50572839
International normalised ratio abnormal 40.88 16.97 17 10393 2826 50591888
Psychomotor hyperactivity 38.64 16.97 24 10386 9277 50585437
Ventricular dyskinesia 37.52 16.97 8 10402 124 50594590
Hyposmia 36.83 16.97 10 10400 444 50594270
Hyperchloraemia 36.83 16.97 11 10399 690 50594024
Drug abuse 36.76 16.97 53 10357 59793 50534921
Joint swelling 34.00 16.97 5 10405 245281 50349433
Pneumonia aspiration 32.73 16.97 36 10374 30968 50563746
Poisoning 32.32 16.97 24 10386 12405 50582309
Urinary retention 32.23 16.97 33 10377 26157 50568557
Hypotension 32.22 16.97 114 10296 235355 50359359
Hypotonia 31.31 16.97 20 10390 8114 50586600
Newborn persistent pulmonary hypertension 31.00 16.97 7 10403 143 50594571
Arthralgia 30.86 16.97 27 10383 438675 50156039
Cor pulmonale acute 30.23 16.97 8 10402 322 50594392
Drug withdrawal syndrome neonatal 29.86 16.97 12 10398 1829 50592885
Hyperthermia 29.81 16.97 19 10391 7677 50587037
Parkinsonism 29.78 16.97 20 10390 8827 50585887
Alopecia 29.68 16.97 7 10403 245040 50349674
Mental disorder 29.43 16.97 29 10381 21962 50572752
Disturbance in attention 29.15 16.97 34 10376 31152 50563562
Diarrhoea 28.91 16.97 48 10362 588428 50006286
Post-anoxic myoclonus 28.66 16.97 5 10405 24 50594690
Polyuria 28.63 16.97 18 10392 7103 50587611
Miosis 28.04 16.97 17 10393 6293 50588421
Drug level increased 26.89 16.97 26 10384 19242 50575472
Fatigue 26.88 16.97 67 10343 707534 49887180
Inappropriate antidiuretic hormone secretion 26.84 16.97 22 10388 13121 50581593
Blood prolactin increased 26.84 16.97 13 10397 3086 50591628
Urine osmolarity increased 26.70 16.97 6 10404 120 50594594
Hallucination, auditory 26.31 16.97 20 10390 10708 50584006
Psychomotor retardation 25.63 16.97 13 10397 3405 50591309
Retroplacental haematoma 25.54 16.97 6 10404 147 50594567
Psychomotor skills impaired 25.23 16.97 11 10399 2053 50592661
Circulatory collapse 24.25 16.97 25 10385 19975 50574739
Cyanosis 24.09 16.97 22 10388 15162 50579552
Mania 23.83 16.97 19 10391 10897 50583817
Hepatocellular injury 23.77 16.97 28 10382 25919 50568795
Shock 23.58 16.97 25 10385 20625 50574089
Muscle rigidity 23.39 16.97 18 10392 9811 50584903
Spasmodic dysphonia 23.36 16.97 5 10405 79 50594635
Otorrhoea 23.22 16.97 9 10401 1247 50593467
Hypokalaemia 23.19 16.97 54 10356 87938 50506776
Obsessive-compulsive disorder 23.02 16.97 12 10398 3328 50591386
Restlessness 22.79 16.97 27 10383 25146 50569568
Product dose omission issue 22.75 16.97 5 10405 183833 50410881
Electrocardiogram QRS complex prolonged 22.73 16.97 14 10396 5330 50589384
Lactic acidosis 22.64 16.97 31 10379 33324 50561390
Asphyxia 22.53 16.97 14 10396 5413 50589301
Nephrogenic diabetes insipidus 22.48 16.97 8 10402 873 50593841
Right ventricular dilatation 21.85 16.97 8 10402 948 50593766
Rash 21.15 16.97 36 10374 437435 50157279
Hyponatraemia 21.09 16.97 55 10355 96084 50498630
Foetal arrhythmia 21.03 16.97 5 10405 129 50594585
Contraindicated product administered 20.71 16.97 3 10407 148955 50445759
Nasopharyngitis 20.59 16.97 7 10403 192920 50401794
Mydriasis 20.07 16.97 17 10393 10610 50584104
Onychophagia 19.71 16.97 4 10406 48 50594666
Peripheral swelling 19.48 16.97 9 10401 205927 50388787
Hyperhidrosis 19.45 16.97 51 10359 89375 50505339
Drug hypersensitivity 19.43 16.97 14 10396 250996 50343718
Cholestasis 19.38 16.97 25 10385 25376 50569338
Drug screen false positive 19.26 16.97 7 10403 812 50593902
Rheumatoid arthritis 18.93 16.97 9 10401 202541 50392173
Tardive dyskinesia 18.80 16.97 14 10396 7265 50587449
Treatment failure 18.61 16.97 3 10407 137634 50457080
Acquired haemophilia 18.59 16.97 7 10403 896 50593818
Apathy 18.35 16.97 14 10396 7534 50587180
Therapeutic product effect decreased 18.32 16.97 3 10407 136047 50458667
Respiratory depression 18.27 16.97 17 10393 11993 50582721
Hyporesponsive to stimuli 18.23 16.97 7 10403 945 50593769
Morbid thoughts 18.03 16.97 6 10404 536 50594178
Headache 17.63 16.97 50 10360 506485 50088229
Rhabdomyolysis 17.60 16.97 30 10380 38997 50555717
Loss of consciousness 17.33 16.97 54 10356 104299 50490415
Toxic skin eruption 17.26 16.97 16 10394 11235 50583479
Infection 17.24 16.97 7 10403 172947 50421767
Swelling 17.18 16.97 10 10400 200862 50393852
Anticholinergic syndrome 16.98 16.97 8 10402 1787 50592927

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicide attempt 262.56 21.69 141 7349 33969 29533068
Therapeutic product effect variable 250.51 21.69 64 7426 1813 29565224
Obsessive-compulsive disorder 247.66 21.69 77 7413 4499 29562538
Antipsychotic drug level below therapeutic 242.46 21.69 63 7427 1911 29565126
Disinhibition 229.67 21.69 64 7426 2543 29564494
Euphoric mood 210.85 21.69 69 7421 4756 29562281
Akathisia 199.44 21.69 72 7418 6670 29560367
Increased appetite 180.25 21.69 65 7425 5999 29561038
Toxicity to various agents 118.89 21.69 180 7310 173481 29393556
Serotonin syndrome 100.93 21.69 60 7430 17452 29549585
Intentional overdose 100.53 21.69 81 7409 38447 29528590
Coma 88.49 21.69 76 7414 39374 29527663
Poisoning deliberate 84.36 21.69 37 7453 5694 29561343
Dyslipidaemia 82.37 21.69 37 7453 6024 29561013
Neuroleptic malignant syndrome 76.91 21.69 49 7441 16099 29550938
Obesity 76.32 21.69 41 7449 9822 29557215
Therapeutic product effect incomplete 72.84 21.69 68 7422 39237 29527800
Leukaemia 70.71 21.69 29 7461 3781 29563256
Prescribed overdose 69.73 21.69 37 7453 8646 29558391
Electrocardiogram QT prolonged 67.88 21.69 63 7427 36074 29530963
Weight increased 66.25 21.69 89 7401 76578 29490459
Sopor 64.38 21.69 38 7452 10896 29556141
Leukopenia 61.87 21.69 73 7417 55130 29511907
Extrapyramidal disorder 54.40 21.69 34 7456 10797 29556240
Intentional self-injury 52.44 21.69 35 7455 12426 29554611
Agitation 48.04 21.69 62 7428 51242 29515795
Somnolence 44.73 21.69 83 7407 93872 29473165
Compartment syndrome 43.24 21.69 18 7472 2434 29564603
Schizoaffective disorder 41.23 21.69 14 7476 1078 29565959
Overdose 41.14 21.69 73 7417 79746 29487291
Renal hypertension 38.97 21.69 9 7481 164 29566873
Drug interaction 36.29 21.69 121 7369 197264 29369773
Loose associations 35.72 21.69 7 7483 55 29566982
Brachial plexus injury 33.85 21.69 7 7483 74 29566963
Tremor 30.12 21.69 61 7429 73477 29493560
Hypothermia 29.67 21.69 22 7468 9217 29557820
Rhabdomyolysis 29.25 21.69 54 7436 60754 29506283
Fatigue 28.72 21.69 23 7467 316798 29250239
Mania 28.65 21.69 21 7469 8642 29558395
Hypertonia neonatal 27.06 21.69 8 7482 392 29566645
Aggression 25.79 21.69 38 7452 35503 29531534
Coma scale abnormal 25.65 21.69 14 7476 3455 29563582
Pneumonia 23.50 21.69 28 7462 320144 29246893
Diarrhoea 23.48 21.69 30 7460 332668 29234369
Bradykinesia 22.99 21.69 13 7477 3434 29563603
Hyperthermia 22.81 21.69 19 7471 9411 29557626
Dyspraxia 22.74 21.69 7 7483 394 29566643
Drug withdrawal syndrome 22.15 21.69 25 7465 17959 29549078
Cough 22.04 21.69 3 7487 126724 29440313
Depressed level of consciousness 21.91 21.69 36 7454 36906 29530131

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 285.78 16.15 201 14375 87414 64396742
Serotonin syndrome 255.61 16.15 140 14436 39142 64445014
Suicide attempt 238.68 16.15 166 14410 70841 64413315
Intentional overdose 229.42 16.15 178 14398 89766 64394390
Poisoning deliberate 168.61 16.15 75 14501 13383 64470773
Neuroleptic malignant syndrome 151.32 16.15 85 14491 24911 64459245
Drug interaction 150.14 16.15 282 14294 361801 64122355
Overdose 134.99 16.15 173 14403 159393 64324763
Sopor 127.74 16.15 81 14495 29580 64454576
Toxicity to various agents 127.49 16.15 264 14312 363249 64120907
Bezoar 105.94 16.15 33 14543 2170 64481986
Electrocardiogram QT prolonged 102.22 16.15 107 14469 79341 64404815
Intentional self-injury 93.02 16.15 66 14510 28978 64455178
Akathisia 85.95 16.15 45 14531 11465 64472691
Somnolence 79.65 16.15 155 14421 203490 64280666
Depressed level of consciousness 76.26 16.15 93 14483 81343 64402813
Obsessive-compulsive disorder 73.94 16.15 31 14545 4787 64479369
Agitation 68.68 16.15 92 14484 88275 64395881
Tremor 60.57 16.15 115 14461 148115 64336041
Tachycardia 59.83 16.15 115 14461 149464 64334692
Antidepressant drug level increased 57.78 16.15 14 14562 356 64483800
Hyperthermia 56.03 16.15 38 14538 15512 64468644
Pain 54.02 16.15 29 14547 553482 63930674
Psychomotor hyperactivity 53.70 16.15 36 14540 14415 64469741
Confusional state 53.04 16.15 154 14422 260990 64223166
Antipsychotic drug level increased 53.03 16.15 25 14551 5090 64479066
Mania 52.11 16.15 37 14539 16249 64467907
Altered state of consciousness 50.41 16.15 52 14524 37850 64446306
Rhabdomyolysis 50.25 16.15 81 14495 91645 64392511
Suicidal ideation 48.24 16.15 67 14509 66475 64417681
Parkinsonism 46.79 16.15 33 14543 14340 64469816
Antipsychotic drug level below therapeutic 44.21 16.15 14 14562 971 64483185
Extrapyramidal disorder 43.97 16.15 36 14540 19516 64464640
Diarrhoea 42.61 16.15 61 14515 722643 63761513
Myoclonus 41.88 16.15 39 14537 25079 64459077
Cerebellar syndrome 41.45 16.15 21 14555 4995 64479161
Pneumonia aspiration 40.47 16.15 58 14518 59213 64424943
Fatigue 39.57 16.15 68 14508 748662 63735494
Renal hypertension 38.69 16.15 9 14567 191 64483965
Psychomotor retardation 38.08 16.15 20 14556 5123 64479033
Arthralgia 37.79 16.15 27 14549 442233 64041923
Hallucination, auditory 37.69 16.15 31 14545 16908 64467248
Sinus tachycardia 37.21 16.15 41 14535 32147 64452009
Therapeutic product effect variable 37.19 16.15 14 14562 1630 64482526
Disinhibition 36.33 16.15 15 14561 2228 64481928
Loose associations 36.18 16.15 7 14569 58 64484098
Euphoric mood 36.07 16.15 21 14555 6570 64477586
Compartment syndrome 35.80 16.15 18 14558 4214 64479942
Peripheral swelling 33.45 16.15 4 14572 209149 64275007
Hepatocellular injury 33.45 16.15 46 14530 45189 64438967
Nasopharyngitis 33.29 16.15 3 14573 196070 64288086
Prescribed overdose 32.80 16.15 31 14545 20300 64463856
Apathy 32.47 16.15 24 14552 11208 64472948
Joint swelling 32.36 16.15 5 14571 215377 64268779
Hyperchloraemia 32.20 16.15 11 14565 968 64483188
Livedo reticularis 32.08 16.15 16 14560 3681 64480475
Brachial plexus injury 32.08 16.15 7 14569 110 64484046
Urinary retention 31.91 16.15 47 14529 49154 64435002
Hypertonia 31.60 16.15 19 14557 6306 64477850
Shock 31.51 16.15 41 14535 38199 64445957
Bronchial hyperreactivity 31.45 16.15 14 14562 2498 64481658
Bradykinesia 30.96 16.15 19 14557 6541 64477615
Muscle rigidity 30.82 16.15 28 14548 17445 64466711
Schizoaffective disorder 30.49 16.15 12 14564 1575 64482581
International normalised ratio abnormal 30.26 16.15 17 14559 4971 64479185
Hyperhidrosis 29.59 16.15 78 14498 124842 64359314
Electrocardiogram QRS complex prolonged 29.57 16.15 21 14555 9223 64474933
Hyposmia 29.32 16.15 9 14567 563 64483593
Miosis 28.94 16.15 24 14552 13242 64470914
Drug abuse 28.70 16.15 80 14496 132294 64351862
Pressure of speech 28.12 16.15 10 14566 991 64483165
Post-anoxic myoclonus 28.02 16.15 5 14571 25 64484131
Coma scale abnormal 28.01 16.15 19 14557 7755 64476401
Polyuria 27.84 16.15 23 14553 12620 64471536
Ventricular dyskinesia 27.80 16.15 8 14568 400 64483756
Circulatory collapse 27.54 16.15 36 14540 33696 64450460
Obesity 26.95 16.15 28 14548 20534 64463622
Inappropriate antidiuretic hormone secretion 26.82 16.15 29 14547 22260 64461896
Asphyxia 26.67 16.15 20 14556 9546 64474610
Infusion related reaction 26.66 16.15 3 14573 164464 64319692
Retroplacental haematoma 26.42 16.15 6 14570 114 64484042
Breast disorder 26.39 16.15 11 14565 1673 64482483
Disturbance in attention 26.30 16.15 39 14537 41035 64443121
Mental disorder 26.03 16.15 31 14545 26414 64457742
Intentional product misuse 25.76 16.15 53 14523 72242 64411914
Rash 25.69 16.15 40 14536 458509 64025647
Speech disorder 25.45 16.15 42 14534 48399 64435757
Seizure 25.22 16.15 89 14487 166803 64317353
Loss of consciousness 24.94 16.15 82 14494 148283 64335873
Febrile neutropenia 24.72 16.15 6 14570 187651 64296505
Cor pulmonale acute 24.48 16.15 8 14568 614 64483542
Generalised tonic-clonic seizure 24.31 16.15 37 14539 39820 64444336
Abdominal pain 24.22 16.15 21 14555 312354 64171802
Hypothermia 24.18 16.15 26 14550 19830 64464326
Drug level increased 24.12 16.15 34 14542 34162 64449994
Blood prolactin increased 24.09 16.15 13 14563 3515 64480641
Mydriasis 24.04 16.15 23 14553 15289 64468867
Nausea 24.03 16.15 94 14482 785706 63698450
Poisoning 23.80 16.15 27 14549 21852 64462304
Psychomotor skills impaired 23.05 16.15 13 14563 3832 64480324
Pneumonia 22.64 16.15 59 14517 559517 63924639
Cough 22.60 16.15 21 14555 302127 64182029
Product dose omission issue 22.42 16.15 8 14568 194739 64289417
Hepatic cytolysis 21.86 16.15 21 14555 14028 64470128
Restlessness 21.58 16.15 35 14541 39750 64444406
Pain in extremity 21.58 16.15 22 14554 303063 64181093
Urine osmolarity increased 21.44 16.15 6 14570 271 64483885
Dyspraxia 21.31 16.15 6 14570 277 64483879
Hypotension 21.22 16.15 153 14423 380821 64103335
Anxiety 20.94 16.15 96 14480 202553 64281603
Otorrhoea 20.87 16.15 9 14567 1488 64482668
Hypokalaemia 20.15 16.15 67 14509 121836 64362320
Pleurothotonus 20.08 16.15 10 14566 2292 64481864
Product use in unapproved indication 20.00 16.15 86 14490 176532 64307624
Clonus 19.91 16.15 14 14562 6053 64478103
Morbid thoughts 19.44 16.15 7 14569 719 64483437
Death 19.43 16.15 51 14525 482654 64001502
Spasmodic dysphonia 19.13 16.15 5 14571 174 64483982
Aggression 19.01 16.15 36 14540 46196 64437960
Nephrogenic diabetes insipidus 18.88 16.15 9 14567 1878 64482278
Anticholinergic syndrome 18.69 16.15 10 14566 2659 64481497
Dyslipidaemia 18.67 16.15 16 14560 9226 64474930
Sepsis 18.44 16.15 15 14561 230326 64253830
Feelings of worthlessness 18.11 16.15 6 14570 480 64483676
Sleep disorder 18.09 16.15 41 14535 59668 64424488
Abulia 18.04 16.15 7 14569 884 64483272
Right ventricular dilatation 17.92 16.15 8 14568 1437 64482719
Hyperreflexia 17.85 16.15 14 14562 7134 64477022
Stupor 17.68 16.15 13 14563 6022 64478134
Headache 17.68 16.15 61 14515 529406 63954750
Rebound effect 17.67 16.15 12 14564 4905 64479251
Disorientation 17.65 16.15 39 14537 55789 64428367
Blood creatine phosphokinase increased 17.50 16.15 40 14536 58518 64425638
Hyponatraemia 17.39 16.15 73 14503 148266 64335890
Increased appetite 17.38 16.15 16 14560 10130 64474026
Drug screen false positive 17.18 16.15 7 14569 1005 64483151
Alopecia 17.13 16.15 8 14568 165682 64318474
Onychophagia 17.06 16.15 4 14572 88 64484068
Irritability 16.85 16.15 30 14546 36716 64447440
Hypernatraemia 16.70 16.15 17 14559 12172 64471984
Therapeutic product effect decreased 16.60 16.15 3 14573 115348 64368808

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AA04 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:48278 serotonergic drugs
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:149553 anticoronaviral drug
MeSH PA D000928 Antidepressive Agents
MeSH PA D000929 Antidepressive Agents, Tricyclic
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D017367 Serotonin Uptake Inhibitors
FDA EPC N0000175752 Tricyclic Antidepressant
CHEBI has role CHEBI:50949 SSRI
CHEBI has role CHEBI:77402 EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Obsessive-compulsive disorder indication 191736004 DOID:10933
Depressive disorder off-label use 35489007
Cataplexy off-label use 46263000
Anxiety off-label use 48694002
Panic disorder off-label use 371631005 DOID:594
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Glaucoma contraindication 23986001 DOID:1686
Hyperthyroidism contraindication 34486009 DOID:7998
Acute nephropathy contraindication 58574008
Epilepsy contraindication 84757009 DOID:1826
Bipolar affective disorder, current episode manic contraindication 191618007
Disease of liver contraindication 235856003 DOID:409
Retention of urine contraindication 267064002
Pheochromocytoma contraindication 302835009
Malignant hyperthermia contraindication 405501007
Myocardial infarction in recovery phase contraindication 418044006
Neuroblastoma contraindication 432328008 DOID:769
Atrioventricular Conduction Defect contraindication




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Separation anxiety Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Clomicalm Tablets Virbac AH Inc. 1
Clomipramine Hydrochloride Tablets Mizner Bioscience LLC 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.04 Basic
pKa2 6.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Kd 7.42 WOMBAT-PK IUPHAR
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 9.70 PDSP CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.28 PDSP
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.24 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 7.45 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 6.82 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.19 PDSP
5-hydroxytryptamine receptor 6 GPCR Ki 6.95 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 8.50 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.34 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 7.41 PDSP
Histamine H1 receptor GPCR Ki 8.01 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.70 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 7.66 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.07 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 7.44 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.89 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 7.42 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 6.32 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 6.69 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter IC50 5.56 CHEMBL
Cytochrome P450 2D6 Enzyme Ki 5.66 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 7.40 DRUG MATRIX
Glutathione S-transferase P Enzyme WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 4.71 CHEMBL
D(1A) dopamine receptor GPCR Ki 6.66 PDSP
D(2) dopamine receptor GPCR Ki 6.95 PDSP
Trypanothione reductase Enzyme Ki 5.19 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 7.14 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.94 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 10.40 CHEMBL
D(2) dopamine receptor GPCR Ki 7.25 CHEMBL
Sodium-dependent noradrenaline transporter Transporter IC50 6.05 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 7.15 CHEMBL
Histamine H1 receptor GPCR IC50 9.70 CHEMBL
Serotonin (5-HT) receptor GPCR IC50 8.30 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 5.30 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 7.29 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 8.08 CHEMBL
Trypanothione reductase Enzyme IC50 5.47 CHEMBL
G protein-activated inward rectifier potassium channel 2 Ion channel BLOCKER IC50 4.40 IUPHAR

External reference:

IDSource
4019687 VUID
N0000147779 NUI
D00811 KEGG_DRUG
17321-77-6 SECONDARY_CAS_RN
2597 RXNORM
4019492 VANDF
4019687 VANDF
C0009010 UMLSCUI
CHEBI:47780 CHEBI
CXX PDB_CHEM_ID
CHEMBL415 ChEMBL_ID
CHEMBL1200710 ChEMBL_ID
DB01242 DRUGBANK_ID
D002997 MESH_DESCRIPTOR_UI
2801 PUBCHEM_CID
2398 IUPHAR_LIGAND_ID
2238 INN_ID
NUV44L116D UNII
373 MMSL
4476 MMSL
d00876 MMSL
003456 NDDF
004614 NDDF
372903001 SNOMEDCT_US
387027004 SNOMEDCT_US
96209002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3025 CAPSULE 25 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3050 CAPSULE 50 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-3075 CAPSULE 75 mg ORAL ANDA 25 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8806 CAPSULE 25 mg ORAL NDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8807 CAPSULE 50 mg ORAL NDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0406-8808 CAPSULE 75 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9906 CAPSULE 25 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9907 CAPSULE 50 mg ORAL NDA 24 sections
ANAFRANIL HUMAN PRESCRIPTION DRUG LABEL 1 0406-9908 CAPSULE 75 mg ORAL NDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2027 CAPSULE 25 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2037 CAPSULE 50 mg ORAL ANDA 25 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0630 CAPSULE 25 mg ORAL ANDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0631 CAPSULE 50 mg ORAL ANDA 24 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0632 CAPSULE 75 mg ORAL ANDA 24 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7038 CAPSULE 25 mg ORAL ANDA 26 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7039 CAPSULE 50 mg ORAL ANDA 26 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-698 CAPSULE 25 mg ORAL ANDA 27 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-699 CAPSULE 50 mg ORAL ANDA 27 sections
clomiPRAMINE Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-700 CAPSULE 75 mg ORAL ANDA 27 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-683 CAPSULE 25 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-684 CAPSULE 50 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride Human Prescription Drug Label 1 16571-685 CAPSULE 75 mg ORAL ANDA 23 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-849 CAPSULE 25 mg ORAL ANDA 21 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-850 CAPSULE 50 mg ORAL ANDA 21 sections
Clomipramine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-851 CAPSULE 75 mg ORAL ANDA 21 sections
Clomipramine hydrochloride Human Prescription Drug Label 1 27241-210 CAPSULE 25 mg ORAL ANDA 23 sections
Clomipramine hydrochloride Human Prescription Drug Label 1 27241-211 CAPSULE 50 mg ORAL ANDA 23 sections
Clomipramine hydrochloride Human Prescription Drug Label 1 27241-212 CAPSULE 75 mg ORAL ANDA 23 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42571-342 CAPSULE 25 mg ORAL ANDA 23 sections
CLOMIPRAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42571-343 CAPSULE 50 mg ORAL ANDA 23 sections